exRNAdisease

General Information

Database ID:

exR0080643

RNA Name:

RPS15

RNA Type:

mRNA

Chromosome:

chr19

Starnd:

Coordinate:

Start Site(bp):

1438358

End Site(bp):

1440494

External Links:

Disease Information

Disease Name:	Fragile X Syndrome
Disease Category:	Congenital, Hereditary, and Neonatal Diseases and Abnormalities
MeSH ID:	D005600
Type:	Diseases Category/Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Alias:	Fragile X Syndromes//Syndrome, Fragile X//Syndromes, Fragile X//Marker X Syndrome//Marker X Syndromes//Syndrome, Marker X//Syndromes, Marker X//Mental Retardation, X-Linked, Associated With Marxq28//X-Linked Mental Retardation and Macroorchidism//X Linked Mental Retardation and Macroorchidism//Fragile X Mental Retardation Syndrome//Martin-Bell Syndrome//Martin Bell Syndrome//Syndrome, Martin-Bell//Fra(X) Syndrome//FRAXE Syndrome//FRAXE Syndromes//Syndrome, FRAXE//Syndromes, FRAXE//Mental Retardation, X-Linked, Associated With Fragile Site Fraxe//Fragile X-F Mental Retardation Syndrome//Mar (X) Syndrome//FRAXA Syndrome//FRAXA Syndromes//Syndrome, FRAXA//Syndromes, FRAXA

Expression Detail

GEO ID:	GSE83556
Description:	Global transcriptome dysregulation in second trimester fetuses with FMR1 expansions
Experimental Design:	Disease vs Control
Case Disease Type:	Fragile X Syndrome
Case Disease SubType:	NA
Case Sample:	Fragile X Syndrome
Control Sample:	Normal
Number of Case:	22
Number of Control:	18
Number of Samples:	40

Regulatory Relationship

mRNA targets:

Gene Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
ABHD17A	chr19	1876810	1885547	-
AC004922.1	chr7	99325879	99394653	+
AC010422.3	chr19	12643831	12648397	-
AC011462.1	chr19	41350853	41425001	+
AC099811.2	chr17	42119674	42154916	-
AC124312.1	chr15	24955034	25000276	+
ACOT13	chr6	24667035	24705065	+
ACTB	chr7	5527148	5563784	-
ACTG1	chr17	81509971	81523847	-
ADO	chr10	62804720	62808479	+
AGPAT2	chr9	136673143	136687457	-
AGPAT3	chr21	43865223	43987592	+
AL136295.3	chr14	24120956	24131829	+
AL139260.3	chr1	38864501	38881617	-
AL928654.3	chr14	105487199	105492267	+
ALDH5A1	chr6	24494867	24537207	+
ALDH9A1	chr1	165662216	165698863	-
ALDOA	chr16	30064164	30070457	+

miRNA targets:

miRNA Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
hsa-miR-155-5p	chr21	25573983	25574006	+
hsa-miR-155-3p	chr21	25574022	25574043	+
hsa-miR-7847-3p	chr11	1880105	1880125	+

circRNA targets:

lncRNA targets:

lncRNA Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
AC002116.1	chr19	36008638	36014235	-
AC004687.1	chr17	58330884	58332508	-
AC005083.1	chr7	20217577	20221700	+
AC009065.2	chr16	2235689	2236913	-
AC009133.5	chr16	29808679	29812227	+
AC016876.2	chr17	7581964	7584086	-
AC027307.3	chr19	1440839	1441938	+
AC090114.2	chr7	128524016	128531069	-
AD000090.1	chr19	35557956	35581954	+
AL022311.1	chr22	37876148	37895563	+

Display:

Experiment Detail

GEO ID:	GSE83556
Sample Source:	Amniotic Fluid
Source Fraction:	Supernatant
Platform:	GPL570
Method:	Microarray
Num of detected RNA Type:	1
Num of detected RNAs of this Type:	17063
Sample treatment protocol:	RNA was extracted from 5-15 mL amniotic fluid supernatant (centrifugation at 350g, 4C, 10, min).
RNA Extract protocol:	All samples were processed using the Qiagen Circulating Nucleic Acid kit with an on-column DNase digestion step to remove genomic DNA. The RNA was then purified and concentrated with the RNeasy MinElute Clean up kit and eluted in RNasefree water.
RNA library preparation protocol:	RNA was converted to cDNA and amplified using the Ovation Pico WTA kit V2 and then purified with the QIAquick PCR Purification kit. Samples were labeled using the Encore Biotin Module (NuGEN, San Carlos, CA)Samples were labeled using the Encore Biotin Module (NuGEN, San Carlos, CA).

Reference